First, the expression of several melanoma surface molecules, serving as ligands for NK cell activating receptors (NKG2D, DNAM-1), was analysed after 24 and 48 h of treatment with BRAFi, MEKi, or the combination thereof. Here, KLRK1 is linked to melanoma.